Kuljit S. Bhatia, Ph.D., has been named vice president of R&D at DPT Laboratories.  
Dr. Bhatia will lead the research and pharmaceutical development group and oversee DPT’s Center of Excellence for R&D in San Antonio. R&D activities at the Center include pre-formulation and formulation development, analytical development and validation, process optimization and transfer to DPT’s Centers of Excellence for Semi-solids and Liquids and Sterile and Specialty Products.
 
Dr. Bhatia has more than 15 years of pharmaceutical experience in drug product development. Previously he was vice president of R&D and Technical Operations at Fougera Pharmaceuticals (formerly Nycomed). While at Fougera, he led pre-formulation and formulation development, analytical development and validation, process development, technical operations, package engineering and CMC project management. Prior to joining Fougera, he held senior R&D positions at Medicis Pharmaceuticals and Mylan Technologies.
 
“Dr. Bhatia brings extensive experience in comprehensive pharmaceutical development services, along with specific expertise in the area of topical pharmaceutical products, which applies directly to the semi-solid and liquid dosage forms that are our focus at DPT,” said Paul Johnson, president of DPT. “His broad understanding of the development process will be a critical asset in our efforts to enhance our continuum of services.”